http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
ZimVie to Report Second Quarter 2025 Financial Results on July 30, 2025
-
ZimVie partners with Osstem Implant for China distribution deal
-
ZimVie Announces Exclusive Distribution Agreement with Osstem Implant to Expand Premium Dental Implant Offering in China
-
ARCHIMED to acquire ZimVie for $19 per share in $730 million deal
-
ZimVie Announces Definitive Agreement to be Acquired by ARCHIMED for $19.00 Per Share in Cash
-
ZimVie Announces Launch of RealGUIDE® Dental Implant Software Suite and Implant Concierge® Service in Japan
-
ZimVie to Participate in the Stifel 2025 Jaws & Paws Conference
-
ZimVie to Participate in the Stifel 2025 Jaws & Paws Conference
-
ZimVie Reports First Quarter 2025 Financial Results
-
ZimVie to Report First Quarter 2025 Financial Results on May 8, 2025
-
ZimVie Pioneers the Future of Molar Restoration with New Immediate Molar Dental Implant System
-
ZimVie to Participate in the 24th Annual Needham Virtual Healthcare Conference
-
ZimVie Inc. (ZIMV) Announces Board Changes
-
ZimVie Announces Upcoming Changes to Company's Board of Directors
-
ZimVie Announces Upcoming Changes to Company's Board of Directors
-
ZimVie Reports Fourth Quarter and Full Year 2024 Financial Results
-
Veradigm Announces Board Expansion and Changes
-
ZimVie to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
-
ZimVie Announces Publication of a Study Supporting the Benefits of Its Implant Surface Technologies
-
ZimVie Reports Third Quarter 2024 Financial Results
-
ZimVie to Present at the UBS Global Healthcare Conference
-
ZimVie to Report Third Quarter Financial Results on October 30, 2024
-
ZimVie Reports Second Quarter 2024 Financial Results
-
ZimVie Announces the Release of RealGUIDE® 5.4 Software Update
-
ZimVie Inc. (ZIMV) Announces FDA Clearance and U.S. Launch of GenTek Restorative Components
-
ZimVie Announces FDA Clearance and U.S. Launch of GenTek® Restorative Components
-
ZimVie to Report Second Quarter Financial Results on August 1, 2024
-
ZimVie to Participate in Upcoming Investor Conferences
-
ZimVie Reports First Quarter 2024 Financial Results
-
ZimVie to Report First Quarter Financial Results on May 8, 2024
-
ZimVie Announces Closing of Sale of Spine Business
-
ZimVie to Participate in the 23rd Annual Needham Virtual Healthcare Conference
-
ZimVie Reports Fourth Quarter and Full Year 2023 Financial Results
-
ZimVie to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
-
ZimVie Inc. (ZIMV) Announces Launch of Next-Generation TSX Implant in Japan
-
ZimVie Announces Launch of Next-Generation TSX® Implant in Japan
-
ZimVie Inc. (ZIMV) to Sell Spine Business to H.I.G. Capital for $375M
-
ZimVie Announces Definitive Agreement to Sell Spine Business to H.I.G. Capital for $375 Million
-
ZimVie Announces Compatibility Between its Vital™ Spinal Fixation System and Brainlab Spine & Trauma Navigation
-
ZimVie Announces Compatibility Between its Vital™ Spinal Fixation System and Brainlab Spine & Trauma Navigation
-
ZimVie Reports Third Quarter 2023 Financial Results and Provides Update to Annual Guidance
-
ZimVie Announces First U.S. Surgery with the 4.5mm Mobi-C® Cervical Disc
-
ZimVie Announces Over 2,000 Children Have Received The Tether™ VBT
-
ZimVie Announces the Launch of Azure™ Multi-Platform Product Solutions
-
ZimVie to Report Third Quarter 2023 Financial Results on November 1, 2023
-
ZimVie Announces the Recent Launch of Biotivity™ A/C Plus Membrane
-
ZimVie (ZIMV) Announces FDA Approval to Launch Mobi-C Hybrid Study
-
ZimVie Announces FDA Approval to Launch Mobi-C® Hybrid Study
-
ZimVie Expands Development Cooperation Agreement with Brainlab AG to Include Co-Marketing
-
ZimVie Inc. (ZIMV) Announces FDA Approval for New Mobi-C Implant

